SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the leader in the development of a new class of small molecule compounds based on endogenous steroid hormones, today announced that the Company’s Chairman and CEO, Richard B. Hollis, will be presenting at the following investor conferences and forums:
